Received April 17, 2021
Accepted October 20, 2021

Objective: Outcome data for oocyte vitrification for fertility preservation are still scarce despite the scientific and technological advances. Studies suggest that patients with cancer have worse outcomes regarding mature vitrified oocytes when compared to healthy patients. Thus, the objective of this study was to evaluate and compare the oocyte vitrification response in patients undergoing elective and onco-fertility preservation. Methods: The ovarian stimulation response was verified by a cross-sectional and observational study, analyzing data from 367 patients between 2009 and 2018, which were divided into elective group (EG; n = 327) and onco-fertility group (OFG; n = 40). The number of follicles, oocytes, mature oocytes, and duration of the cycle was evaluated, which were compared with clinical and ovarian stimulus data between groups. Results: A significant difference in women age (31.3 ± 5.8 vs. 37.0 ± 2.9 years; p <0.01) and basal values of Follicle Stimulating Hormone (FSH), (4.0 [3.3 – 6.2] vs. 9.0 [5.4 – 9.9] mIU/mL; p <0.01) were observed. When adjusting data for age, FSH and Gonadotropin-releasing Hormone protocols, no significant difference in the number of vitrified mature oocytes between the two groups were observed (6.0 [3.0–11.0] vs. 7.0 [3.0–12.0]; p=0.11). Conclusion: Thus, patients undergoing elective and onco-fertility preservation seem to respond similarly to controlled ovarian stimulation for fertility preservation. Breast cancer was the most frequent in the OFG (67%).